Acute lymphoblastic leukemia (ALL) is the most frequent neoplasm in children, whereas it is more rare in adults. Over the last decades, there has been a considerable improvement in the management and outcome of childhood ALL, with CR rates and long-term survivals reaching 95% and 80%, respectively. At variance, in adults the clinical scenario is significantly different, mostly in terms of survival rates, which generally do not exceed 40%.

Several features can at least in part explain this marked difference in prognosis; these include -- among others -- more intensive regimens, less side effects and a higher compliance to aggressive chemotherapy schedules in children, while in adults the toxic effects often represent a considerable limit to the administration of adequate drug doses and to the correct timing of chemotherapy. As a proof of principle of these concepts, it has been widely reported that adolescents and young adults (also called AYA) treated with pediatric-like regimens, have a superior outcome.

Moreover, a number of biologic features are responsible for the different clinical scenario, such as an increased incidence in older patients of the *BCR/ABL* and *ALL1/AF4* transcripts, known to have a negative impact on prognosis, and a decreased incidence of the *ETV6/RUNX1* rearrangement, associated with a favorable outcome; furthermore, it has been reported that older patients (\>60 years) tend to have a decreased male/female ratio and a decreased incidence of organomegaly.

Taking advantage of the availability of two large databases of the Italian multicenter protocols AIEOP (Associazione Italiana Ematologia ed Oncologia Pediatrica) and GIMEMA (Gruppo Italiano Malattie EMatologiche dell\'Adulto) for the treatment of pediatric and adult ALL, respectively, we have recently evaluated retrospectively the clinicobiologic features of more than 5000 patients, subdivided in different age groups (1--5, 5--10, 10--14, 14--18, 18--25, 25--20, 30--40, 40--50, 50--60 years).

The analysis of this large cohort of patients has allowed to highlight, as expected, a peak in the incidence of ALL in the age groups 1--5 and 5--10, with a progressive decrease from 10 to 30 years and an increase from 30 years onwards. Interestingly, gender distribution highlighted an overall lower incidence of females: this phenomenon was remarkable between 14--50 years and disappeared in the 50--60 age-cohort. Furthermore, there was a significant association between gender and immunophenotype, T-ALL being more frequent in males up to the 4^th^ decade. Molecular screening showed that the *ETV6/RUNX1+* virtually disappeared in adult patients; furthermore, it also highlighted a progressive increase of two molecular rearrangements known to be associated with a very poor outcome, namely *ALL1/AF4* and *BCR/ABL,* the latter being detected in more than 50% of individuals in the 6^th^ decade of life.

These findings provide a further biologic rationale for the progressive implementation of novel targeted therapeutic approaches directed against specific targets. Two illuminating examples in this sense are given by two consecutive Italian protocols for the treatment of adult *BCR/ABL*+ ALL patients. The first protocol, the GIMEMA LAL 0201B study, enrolled only elderly patients (\>60 years) and was based on the administration of corticosteroids for the first week of treatment followed thereafter by imatinib, the first tyrosine kinase inhibitor specifically directed against the ABL protein, at the dose of 800 mg daily, associated to steroids without further chemotherapy as frontline treatment. The median age was 69 years and, remarkably, all patients obtained a complete hematologic remission, with a consistent reduction of the BCR-ABL transcripts. This schedule allowed a reduced hospitalization, was not coupled to major toxicities and treatment was well tolerated.

In the second study, the GIMEMA LAL1205 protocol, designed for adult individuals (\>18 years) with a BCR/ABL+ ALL, dasatinib -- one of the most potent second-generation tyrosine kinase inhibitors -- was administered 70 mg twice daily for a total of 84 days, and was preceded by a week of corticosteroids: also with this schedule, all patients obtained a complete hematologic remission and had a good quality of life.

Overall, these two studies have shown that also elderly patients with *BCR/ABL*+ ALL, previously considered eligible only for palliative treatment strategies, may be spared chemotherapy and successfully managed with a targeted therapeutic approach. Furthermore, they underline the importance of performing a precise diagnostic work-up at all ages, with the final goal of providing all patients with the best therapeutic option.

Another example is represented by the specific overexpression of the Flt3 kinase in patients carrying the ALL1/AF4 rearrangement and in a subgroup of children and adults without known molecular aberrations. Although this finding has so far not translated into the clinical practice, it is intriguing to speculate that regimes including Flt3 inhibitors might be of benefit for ALL patients who have high expression levels of this kinase and who are known to have an unfavorable prognostic likelihood.

In conclusion, stratification of patients according to age groups is associated with important clinical and biologic features that might be in part responsible of the marked differences in the outcome witnessed in children and adults with ALL.

The introduction of *pediatric-like* regimes for the management of young adults is progressively changing the outcome for this subgroup of patients, although some important questions still remain open. In particular, a clear cut-off for the definition of young adults has so far not been established and the burden of toxicities associated with these more aggressive therapeutic regimens in terms of compliance to treatment, quality of life and overall survival is at present not conclusively defined for the different age ranges.
